SCHEMBL1574780

SCHEMBL1574780

CN(C)C1CN(C(=O)Nc2ccc3ccccc3c2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.52
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 1/20 0.47
HIF1A Q16665 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.47
RAB9A P51151 6/20 0.47
NPC1 O15118 5/20 0.47
MAPT P10636 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
POLB P06746 1/20 0.46
EPHX2 P34913 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.45
RECQL P46063 1/20 0.44
FAAH O00519 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574526 0.87 KDM4E (0.48) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL1575249 0.86 KDM4E (0.49) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL1575311 0.86 KDM4E (0.49) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL1575334 0.84 KDM4E (0.47) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL1575218 0.83 GAA (0.51) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL830019 0.82 KDM4E (0.62) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL1574388 0.82 KDM4E (0.48) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL1575057 0.82 KDM4E (0.46) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL1574878 0.81 NPC1 (0.61) KDM4EALDH1A1RAB9ANPC1MAPT
SCHEMBL1574541 0.80 UBE2M (0.45) KDM4EALDH1A1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB KDM4E 516/4885ALDH1A1 1445/4885MEN1 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.